Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
- 30 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurological Sciences
- Vol. 42 (10), 4193-4202
- https://doi.org/10.1007/s10072-021-05105-5
Abstract
Background Erenumab is a monoclonal antibody blocking the calcitonin gene-related peptide receptor, which has been approved for the preventive treatment of chronic migraine (CM). The aim of this study was to explore the safety and effectiveness of erenumab in patients suffering from CM and medication overuse headache (MOH) in a real-life setting, up to 1 year. Methods Data regarding 81 patients treated with erenumab were retrospectively analyzed. Every 3 months, the following variables were collected: the mean number of headache days per month (headache index (HI)), the average number of painkillers taken per month (analgesic consumption (AC)), the mean number of days with painkiller consumption (number of days on medication (NDM)), the headache intensity (numeric rating scale (NRS) score), the 6-item Headache Impact Test (HIT-6), and the Self-Reported Instrument to Assess Work-Related Difficulties in Patients With Migraine (HEADWORK) scores. Results The HI, AC, and NDM and the NRS, HIT-6, and HEADWORK scores were significantly lower at every time point from the 3rd month onward compared to baseline (all P < 0.0001). No significant differences were found between patients who underwent painkiller detoxification before starting erenumab and those who did not (all P > 0.05). No significant differences were found between patients taking erenumab in combination with other preventive treatments and the ones taking it alone (all P >= 0.05). Five patients dropped out because of adverse events, which resolved after stopping erenumab. Conclusion Erenumab was safe and effective for CM complicated with MOH. Painkiller withdrawal and the association with other preventive treatment(s) seem useless.This publication has 39 references indexed in Scilit:
- Adherence to oral migraine-preventive medications among patients with chronic migraineCephalalgia, 2014
- Economic Burden and Costs of Chronic MigraineCurrent Pain and Headache Reports, 2013
- Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samplesThe Journal of Headache and Pain, 2012
- Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention StudyHeadache: The Journal of Head and Face Pain, 2012
- Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic reviewCephalalgia, 2011
- Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia, 2010
- Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide riskThe Journal of Headache and Pain, 2009
- Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective StudyCephalalgia, 2008
- Rational Combination Therapy in Refractory MigraineHeadache: The Journal of Head and Face Pain, 2008
- Evaluation of two devices for improving thermal control of premature infants in transportCritical Care Medicine, 1984